People ask me questions about stem cells all the time so I decide to do a new blog series answering your questions. Today’s post is the first in this new stem cell Q&A series. Past series have included my Elephant in the Lab series that provides some insights into the craziness that sometimes goes on […]
Patients stem cell Q&A#1: can clinic injections cause GVHD? Read More »
What’s Liveyon up to these days? A new, somewhat mysterious short film that serves as an advertisement for unproven exosomes has some of us scratching our heads. It seems to point to Liveyon. Can you guys as readers of The Niche help solve the puzzle of who’s behind this wild “cinematic commercial” and what the
Mystery of wild sci-fi film ad for unproven exosomes: Liveyon? Read More »
Every year in December and early January I do a post predicting some key events for the stem cell and regenerative medicine field for the upcoming year and today’s post contains my predictions for 2020. You can see my past 2019 predictions along with my grades for them here. I gave myself a B+ for
20/20 vision? The Niche’s 20 stem cell & regenerative medicine predictions for 2020 Read More »
Last year around this time I took my annual plunge to make 20 predictions for the coming year for the stem cell and regenerative medicine field. I even made a crystal ball graphic to highlight the complexity of the stem cell ecosystem into which these predictions were embedded (see image) for 2019. How’d I do?
B+ on my report card on my 20 stem cell predictions for 2019 Read More »
Umbilical “stem cell” supplier Liveyon has suspended sales of its products according to the WaPo after a harsh FDA warning letter. While not fully shutting off the tap to the perinatal stem cell clinic universe, as other suppliers including in Utah seem to be continuing, this Liveyon voluntary hold will equal a major reduction in
Why did clinic supplier Liveyon halt sales but others kept going despite FDA? Read More »
Friday and Saturday showed a burst in FDA activity related to unproven stem cells and regenerative products including a warning letter to the unproven perinatal “stem cell” provider Liveyon. This was an unusual 48-hour period and a very good one for those who believe in science-based regenerative medicine but in my view a bad day
FDA spike: clinic supplier Liveyon warning letter & 483s; notice on exosome harms Read More »
The FDA just sent another untitled letter to a producer of a potentially non-compliant perinatal “stem cell” product that may be an unapproved drug. This follows past non-warning letters and/or inspection reports made public to Liveyon, R3 Stem Cell, Stemell, and others. RAPS has more on the story of the new letter here. This newest
Another FDA letter to a stem cell clinic supplier: what’s the agency’s long game? Read More »
I’m relatively new to podcasts, but am enjoying a new stem cell-focused one called Bad Batch by medical journalist Laura Beil, which I’ve been listening to in the car as I commute. I just finished episode three. I’m curious to hear how the next few episodes of the story unfold. I talked and emailed with
Bad Batch podcast is must listen for stem cell community Read More »
After almost a decade blogging about stem cells from just about every angle, it’s interesting to consider trends in the types of questions I get asked such as this much more common one now as compared to 2010: How much is stem cell therapy? What does a patient pay on average for stem cells in
How much is stem cell therapy? 2019 cost poll results Read More »
This afternoon I attended and gave public comment at the Medical Board of California stem cell task force meeting on unproven stem cell clinics. There were about 40 people attending. In part this meeting is a consequence of the national governing organization of state medical boards, the Federation of State Medical Boards (FSMB) having worked
Report from Medical Board of California meeting on stem cell clinics Read More »